Literature DB >> 15099351

Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.

T P Leren1.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis. Mutations within this gene have previously been found to segregate with hypercholesterolemia. In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded. Two novel missense mutations were detected in the catalytic subdomain of the PCSK9 gene. Two patients were heterozygotes for D374Y, and one patient was a double heterozygote for D374Y and N157K. D374Y segregated with hypercholesterolemia in the two former families where family members were available for study. Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099351     DOI: 10.1111/j.0009-9163.2004.0238.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  60 in total

1.  PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.

Authors:  Mali Liu; Guoxin Wu; Jennifer Baysarowich; Michael Kavana; George H Addona; Kathleen K Bierilo; John S Mudgett; Guillaume Pavlovic; Ayesha Sitlani; John J Renger; Brian K Hubbard; Timothy S Fisher; Celina V Zerbinatti
Journal:  J Lipid Res       Date:  2010-05-07       Impact factor: 5.922

2.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Authors:  Ingrid K Kotowski; Alexander Pertsemlidis; Amy Luke; Richard S Cooper; Gloria L Vega; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-01-20       Impact factor: 11.025

3.  PCSK9 - A New and Potent Approach to Lowering Cholesterol.

Authors:  Thomas F Whayne
Journal:  Oman Med J       Date:  2013-05

4.  Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.

Authors:  Gregory P Hess; Pradeep Natarajan; Kamil F Faridi; Anna Fievitz; Linda Valsdottir; Robert W Yeh
Journal:  Circulation       Date:  2017-10-30       Impact factor: 29.690

5.  Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Authors:  Ali Ben Djoudi Ouadda; Marie-Soleil Gauthier; Delia Susan-Resiga; Emmanuelle Girard; Rachid Essalmani; Miles Black; Jadwiga Marcinkiewicz; Diane Forget; Josée Hamelin; Alexandra Evagelidis; Kevin Ly; Robert Day; Luc Galarneau; Francois Corbin; Benoit Coulombe; Artuela Çaku; Vincent S Tagliabracci; Nabil G Seidah
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-05       Impact factor: 8.311

6.  The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain.

Authors:  Eric N Hampton; Mark W Knuth; Jun Li; Jennifer L Harris; Scott A Lesley; Glen Spraggon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

7.  APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.

Authors:  Ting Fu; YangYang Guan; Junjie Xu; Yan Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-05-09       Impact factor: 4.698

8.  Genetic variation and atherosclerosis.

Authors:  Erik Biros; Mirko Karan; Jonathan Golledge
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

9.  A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.

Authors:  Nidhi Gupta; Niels Fisker; Marie-Claude Asselin; Marie Lindholm; Christoph Rosenbohm; Henrik Ørum; Joacim Elmén; Nabil G Seidah; Ellen Marie Straarup
Journal:  PLoS One       Date:  2010-05-17       Impact factor: 3.240

10.  Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.

Authors:  Hai Li; Bin Dong; Sahng Wook Park; Hyun-Sook Lee; Wei Chen; Jingwen Liu
Journal:  J Biol Chem       Date:  2009-08-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.